David A. Simon
@davidasimon.bsky.social
Associate Professor, Northeastern University School of Law
www.davidasimon.us
Co-Director, Amy J. Reed Collaborative for Medical Device Safety
https://www.safemedicaldevices.org/
Researcher, the CLASSICA Project
https://classicaproject.eu/team/
www.davidasimon.us
Co-Director, Amy J. Reed Collaborative for Medical Device Safety
https://www.safemedicaldevices.org/
Researcher, the CLASSICA Project
https://classicaproject.eu/team/
saw a table from microsoft that AI will be very likely to displace historians and I wonder if the people who made the chart really contemplated what historians do.
November 10, 2025 at 7:21 PM
saw a table from microsoft that AI will be very likely to displace historians and I wonder if the people who made the chart really contemplated what historians do.
Is this ever appropriate or do I have to make a section IV.
November 7, 2025 at 8:40 PM
Is this ever appropriate or do I have to make a section IV.
always the problem. draft is nearly finished at 17000 words. then I edit and now its 21,000 words. want to shave but can't figure out what's best given what I need to cover. I think i will save it for another, more general paper--perhaps an online essay.
November 7, 2025 at 2:55 PM
always the problem. draft is nearly finished at 17000 words. then I edit and now its 21,000 words. want to shave but can't figure out what's best given what I need to cover. I think i will save it for another, more general paper--perhaps an online essay.
Many of us know what it's like to watch a family member develop early-onset Alzheimer's - sometimes more than one. It is horrible, and it should motivate us to fund more research into the disease and treatments.
www.inquirer.com/health/a/rot...
www.inquirer.com/health/a/rot...
Former Rothman CEO Mike West didn’t want to burden his family with his Alzheimer’s. He quietly planned his suicide.
Only 200,000, or 3%, are diagnosed with Alzheimer's before age 65. Such an early onset means the disease is more likely to progress rapidly and shorten their lives.
www.inquirer.com
November 7, 2025 at 1:06 PM
Many of us know what it's like to watch a family member develop early-onset Alzheimer's - sometimes more than one. It is horrible, and it should motivate us to fund more research into the disease and treatments.
www.inquirer.com/health/a/rot...
www.inquirer.com/health/a/rot...
Too early to tell but if things continue the Bulls will be the biggest surprise in sports. And it would be a welcome surprise
November 5, 2025 at 4:56 PM
Too early to tell but if things continue the Bulls will be the biggest surprise in sports. And it would be a welcome surprise
The reality is it costs a lot of money to fund research and the only viable entity that can do it in most cases is the government
www.statnews.com/2025/11/04/a...
www.statnews.com/2025/11/04/a...
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down
Exclusive: Arena Bioworks, the buzzy research institute that launched with $500 million to support a decade of scientific R&D, is abruptly shutting down, STAT has learned.
www.statnews.com
November 5, 2025 at 12:15 PM
The reality is it costs a lot of money to fund research and the only viable entity that can do it in most cases is the government
www.statnews.com/2025/11/04/a...
www.statnews.com/2025/11/04/a...
Just a reminder I have posted conferences in IP, health, law & humanities, & general here. Happy to add.
www.davidasimon.us/conferences
www.davidasimon.us/conferences
Conferences | David A. Simon
www.davidasimon.us
November 4, 2025 at 1:21 PM
Just a reminder I have posted conferences in IP, health, law & humanities, & general here. Happy to add.
www.davidasimon.us/conferences
www.davidasimon.us/conferences
Funny bears media is so predictable. The team is a middling offense that should be much better - with a defense that stinks if it can’t get turnovers. But ok they are amazing now 🙄
November 3, 2025 at 9:16 PM
Funny bears media is so predictable. The team is a middling offense that should be much better - with a defense that stinks if it can’t get turnovers. But ok they are amazing now 🙄
@saragerke.bsky.social and I have a new article out in JAMA J. of Ethics
journalofethics.ama-assn.org/article/how-...
journalofethics.ama-assn.org/article/how-...
November 3, 2025 at 6:09 PM
@saragerke.bsky.social and I have a new article out in JAMA J. of Ethics
journalofethics.ama-assn.org/article/how-...
journalofethics.ama-assn.org/article/how-...
Reposting my paper because it was not distributed in many SSRN e-journals--maybe it's a weird fit.
papers.ssrn.com/sol3/papers....
papers.ssrn.com/sol3/papers....
November 3, 2025 at 12:48 PM
Reposting my paper because it was not distributed in many SSRN e-journals--maybe it's a weird fit.
papers.ssrn.com/sol3/papers....
papers.ssrn.com/sol3/papers....
Whatever the actual facts, there are questions about the legal authority to launch a new “voucher” program
www.nytimes.com/2025/11/02/h...
www.nytimes.com/2025/11/02/h...
F.D.A. Drug Unit Chief Is Placed on Leave, and Cites a ‘Toxic’ Environment
www.nytimes.com
November 2, 2025 at 11:00 PM
Whatever the actual facts, there are questions about the legal authority to launch a new “voucher” program
www.nytimes.com/2025/11/02/h...
www.nytimes.com/2025/11/02/h...
Always a sobering reminder
November 2, 2025 at 10:56 PM
Always a sobering reminder
Bears are the same as always except their defense isn’t very good
November 2, 2025 at 7:23 PM
Bears are the same as always except their defense isn’t very good
Reposted by David A. Simon
"We crave simple solutions to complex problems. When data disappoint, we substitute belief. . . . Regulators see public demand and think, why stand in the way? The phrase 'worth a try' becomes federal policy."
www.statnews.com/2025/11/02/q... via @statnews.com
www.statnews.com/2025/11/02/q... via @statnews.com
A sports device to ‘protect the brain’ illustrates a major problem with the FDA de novo pathway
“This is not just about one device. It’s about what happens when institutions grow comfortable living in their own ambiguity and hiding behind opacity.”
www.statnews.com
November 2, 2025 at 1:39 PM
"We crave simple solutions to complex problems. When data disappoint, we substitute belief. . . . Regulators see public demand and think, why stand in the way? The phrase 'worth a try' becomes federal policy."
www.statnews.com/2025/11/02/q... via @statnews.com
www.statnews.com/2025/11/02/q... via @statnews.com
Just learned the term content brain it explains so much
November 1, 2025 at 7:00 PM
Just learned the term content brain it explains so much
Reposted by David A. Simon
📣 The University of Florida Levin College of Law is looking for a tax Visiting Assistant Professor (VAP) starting in Fall 2026. Application details at the link! #TaxJobs #LegalAcademia #VAP
explore.jobs.ufl.edu/en-us/job/53...
explore.jobs.ufl.edu/en-us/job/53...
University of Florida - Details - Visiting Assistant Professor
explore.jobs.ufl.edu
November 1, 2025 at 1:00 PM
📣 The University of Florida Levin College of Law is looking for a tax Visiting Assistant Professor (VAP) starting in Fall 2026. Application details at the link! #TaxJobs #LegalAcademia #VAP
explore.jobs.ufl.edu/en-us/job/53...
explore.jobs.ufl.edu/en-us/job/53...
Creating a central call center to schedule appointments that requires the scheduler to email the doctors office is not efficient. And yet
October 31, 2025 at 3:33 PM
Creating a central call center to schedule appointments that requires the scheduler to email the doctors office is not efficient. And yet
Reposted by David A. Simon
Opinion | Resistance to Trump Isn’t Enough
www.nytimes.com
October 31, 2025 at 10:06 AM
had I known it was going to be recorded by video, I would have looked a little different 😃
Watch video: In an interview with Medical Economics, Professor David Simon @davidasimon.bsky.social explores the emerging liability questions that will shape healthcare‘s AI future. @medicaleconomics.bsky.social
www.medicaleconomics.com/view/definin...
www.medicaleconomics.com/view/definin...
Defining AI liability: A conversation with David A. Simon, J.D., LL.M., Ph.D. | Medical Economics
How will artificial intelligence reshape the rules of medical malpractice? Northeastern University’s David Simon unpacks the legal, ethical and practical dilemmas now confronting physicians, hospitals...
www.medicaleconomics.com
October 31, 2025 at 12:13 PM
had I known it was going to be recorded by video, I would have looked a little different 😃
found this guy on my walk
October 30, 2025 at 8:10 PM
found this guy on my walk
I see these headlines but I don't see the evidence that AI is the culprit. More likely seems hiring too many people during the pandemic
www.wsj.com/economy/jobs...
www.wsj.com/economy/jobs...
Tens of Thousands of White-Collar Jobs Are Disappearing as AI Starts to Bite
Companies ranging from Amazon to Target are sending workers into an unwelcoming market.
www.wsj.com
October 29, 2025 at 6:20 PM
I see these headlines but I don't see the evidence that AI is the culprit. More likely seems hiring too many people during the pandemic
www.wsj.com/economy/jobs...
www.wsj.com/economy/jobs...
Reposted by David A. Simon
👇👇
Now in @jama.com: @greerdonley.bsky.social, Lewis Grossman & I explain that these preemption cases, while specifically about mifepristone, have implications for FDA and state drug regulation, biomedical innovation, and patient access more generally.
jamanetwork.com/journals/jam...
Now in @jama.com: @greerdonley.bsky.social, Lewis Grossman & I explain that these preemption cases, while specifically about mifepristone, have implications for FDA and state drug regulation, biomedical innovation, and patient access more generally.
jamanetwork.com/journals/jam...
October 29, 2025 at 3:02 PM
👇👇
Now in @jama.com: @greerdonley.bsky.social, Lewis Grossman & I explain that these preemption cases, while specifically about mifepristone, have implications for FDA and state drug regulation, biomedical innovation, and patient access more generally.
jamanetwork.com/journals/jam...
Now in @jama.com: @greerdonley.bsky.social, Lewis Grossman & I explain that these preemption cases, while specifically about mifepristone, have implications for FDA and state drug regulation, biomedical innovation, and patient access more generally.
jamanetwork.com/journals/jam...
